Analysis of serum phosphate control and phosphate binder utilization in incident hemodialysis patients
| Autor: | Fernando Gibson, Kimberly Farrand, J. Brian Copley, Jamie Heise, Moshe Fridman, Michael Keith, Lynne Poole |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
medicine.medical_specialty
medicine.drug_class medicine.medical_treatment International Journal of Nephrology and Renovascular Disease Gastroenterology End stage renal disease chemistry.chemical_compound Hyperphosphatemia Internal medicine medicine In patient hyperphosphatemia Dialysis Original Research end-stage renal disease business.industry Serum phosphate Phosphate medicine.disease Surgery Phosphate binder chemistry Nephrology Hemodialysis business chronic kidney disease |
| Zdroj: | International Journal of Nephrology and Renovascular Disease |
| ISSN: | 1178-7058 |
| DOI: | 10.2147/ijnrd.s58037 |
| Popis: | Kimberly F Farrand,1 J Brian Copley,1 Jamie Heise,1 Moshe Fridman,2 Michael S Keith,1 Lynne Poole3 1Shire, Wayne, PA, USA; 2AMF Consulting, Los Angeles, CA, USA; 3Shire, Basingstoke, UK Abstract: The purpose of this study was to conduct a retrospective analysis of serum phosphate level variability in patients new to hemodialysis (HD) and to identify patient characteristics associated with this variability. The medical records of 47,742 incident HD patients attending US outpatient dialysis centers between January 1, 2006 and March 31, 2009 were analyzed. Monthly mean serum phosphate levels determined over a 6-month evaluation period (months 4–9 after HD initiation) were assigned to one of three strata: low (1.78 mmol/L [>5.5 mg/dL]). Patients were classified into one of six serum phosphate variability groups based on variability among monthly mean phosphate levels over the 6-month evaluation period: consistently target; consistently high; high-to-target; high-to-low; target-to-low; or consistently low. Only 15% of patients (consistently target group) maintained monthly mean serum phosphate levels within the target range throughout the 6-month evaluation period. Age, Charlson comorbidity index, serum phosphate, and intact parathyroid hormone levels prior to HD initiation were strongly associated (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|